Page 57 - Medication Guide News Today

Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology -- Early data from ongoing PROTECT trial suggest stable and durable response to KRYSTEXXA (pegloticase injection) therapy in treating uncontrolled gout among people with kidney transplants -- -- Data on the companys investigational compound (HZN-4920) under evaluation for rheumatoid arthritis will be presented during an oral session on June 3 at 10:15 a.m. CEST -- Horizon Therapeutics plc (N...

ABBVie today announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing risankizumab 360 mg achieved the co-primary endpoints of endoscopic response and clinical remission at one year in adult patients with moderate to severe Crohn's disease. 1 In this study, patients who responded to 12 weeks of risankizumab intravenous induction treatment were re-randomized to receive risankizumab 180 ...

Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis - Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo(1) - The safety profile of Cosentyx in pediatric patients with plaque psoriasis was demonstrated in two Phase III trials(1) - Plaque psoriasis is a chronic, inflammatory disease that ...

Zeposia the first and only oral sphingosine 1-phosphate receptor modulator approved for ulcerative colitis 1 represents a new way of treating this chronic immune-mediated disease 2 Zeposia demonstrated significant improvements across all primary and key secondary efficacy endpoints including clinical remission, clinical response, endoscopic improvement and endoscopic-histologic mucosal improvement versus placebo at ...

(0) -- Trial evaluates opportunity to improve outcomes based on emerging data that immunomodulation may offer clinical benefit -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in the ADVANCE trial evaluating the concomitant use of KRYSTEXXA (pegloticase injection) with methotrexate for people with uncontrolled gout who were not able to achieve a complete response when previously treated with KRYSTEXXA monotherapy. For people with chronic gout refractory ...

ABBVie today announced data from its migraine portfolio will be presented at the 2021 American Headache Society Annual Scientific Meeting, to be held virtually June 3-6 . A total of 23 abstracts, including four podium presentations, will be shared from a broad range of studies across ABBVie's migraine portfolio. "Migraine is an often-debilitating disease that affects millions of people in the prime of their lives, ...

For those who may not know, endometriosis happens when tissue similar to the lining of the uterus (womb) grows outside of the uterus, where it doesn’t belong. It’s a common health problem for women, according to the Office on Women’s Health, with an estimated 1 in 10 women of reproductive age in the U.S. diagnosed with the disease. These endometriosis growths (or lesions) can be extremely painful, and at times debilitating. There is no cure for endometriosis, and despite various treatment...

Message : Required fields NORTH CHICAGO, Ill., May 24, 2021 /PRNewswire/ -- Late-breaking data analyses presented by AbbVie (NYSE: ABBV) at Digestive Disease Week ® (DDW) Virtual Conference 2021 showed significantly greater proportions of patients with moderately to severely active Crohns disease treated with both doses of investigational risankizumab (600 mg or 1200 mg) met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo (p

Late-breaking data analyses presented by ABBVie at Digestive Disease Week ® Virtual Conference 2021 showed significantly greater proportions of patients with moderately to severely active Crohn's disease treated with both doses of investigational risankizumab met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo andor biologic therapy . The MOTIVATE trial ...

ABBVie  today announced The Lancet published primary analysis results from the pivotal global Phase 3 clinical trials Measure Up 1, Measure Up 2 and AD Up evaluating RINVOQ ® in adults and adolescents with moderate to severe atopic dermatitis who were candidates for systemic treatment. The results were published in two separate manuscripts as part of the May 22, 2021 issue of The Lancet. The publication of ...